RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
 Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Jul 21, 2011 - 1:15:56 AM
News Report
Medical News Channel

subscribe to Medical News newsletter
Medical News

   EMAIL   |   PRINT
Human trials for single injection cancer cure to begin

Mar 7, 2010 - 3:33:17 PM
He added that right from finance to time, the treatment will be more human friendly.

 
[RxPG] New Delhi, March 7 - Treating cancer with just one injection? It may sound unbelievable, but an Indian medical institute is soon to start human trials to treat cancer in six weeks through a solitary injection dose.

'It's a single injection dose medicine to treat cancer. If everything goes fine, it will be a novel medical breakthrough,' Kushagra Kataria, chief executive officer of Artemis Health Institute in Gurgaon, told IANS.

'We are set to start human trials in May with a limited number of patients,' said Kataria, a thoracic oncologist.

He said medical scientists will inject 'oncolytic virus' into the human body, which will target the cancer cells and treat patients with much precision and success. Subjects for this trial would be primarily patients suffering from lung, neck and cervical cancer.

Artemis, one of the leading tertiary care hospitals in India, will be conducting the trials in collaboration with Memorial Sloan-Kettering Cancer Centre in New York.

Kataria said animal trials conducted in Britain had given encouraging results. 'The drug has already been tested on mice with human cancer tumours. It has given optimistic results.'

In the current conventional therapy, cancer treatment affects healthy cells along with cancerous cells but in the new treatment, the medicine will not affect any other cells of the body other than the cancerous tumour and cells.

'It will be targeted therapy,' Kataria explained. 'If everything goes well, we believe it will reduce all side effects of the conventional treatment.'

He added that right from finance to time, the treatment will be more human friendly.

While tens of thousands of people die every year due to cancer, India is home to nearly two million patients at any given period of time.




Advertise in this space for $10 per month. Contact us today.


Related Medical News News
Women delivers baby near lift in Noida hospital
Obesity on rise in school children: Study
Over 10,000 dengue cases in India this year
NRI doctors demands removal of 'tainted' medical council members
Watch out for sexually transmitted 'superbug': Expert
Panel stresses on infection control in hospitals
Healthcare cost up 22 times in rural areas, shows study
Superbug exists, but nothing alarming: Walia
No power problem at AIIMS: Official
40 percent Indians embarrassed to ask for contraceptives

Subscribe to Medical News Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

All rights reserved by RxPG
Contact Us